Boulevard Bio has launched with $65 million to develop treatments that reset the immune system in autoimmune disease — co-founded by one of the field’s most influential figures.

Announced August 12, 2026 and backed by Deerfield Management via its 3DC biotech-building arm, the company is co-founded by physician-scientist Georg Schett. Deerfield’s Frank Nestle is a co-founder, and Mahesh Karande, formerly of Omega Therapeutics, is CEO.

Why Schett’s involvement matters

About five years ago Schett showed that CAR T-cell therapy could drive lupus into complete remission — a result since extended to other inflammatory disorders and the principal driver of the immune reset movement.

That work changed what the field thought possible. Autoimmune disease had been managed by suppression: drugs taken continuously to hold the immune system down, with relapse expected on stopping. Patients achieving drug-free remission after a single treatment was categorically different.

The interpretation is that deep depletion of B cells allows the immune system to reconstitute without the autoreactive population — not suppression of an ongoing process but a reset of it.

A company co-founded by the person who produced that observation carries credibility that a comparable startup would not.

Why not simply do CAR-T

The field is racing to translate those results into treatments that are safer, cheaper and easier to give than cell therapy, and each of those adjectives identifies a real obstacle.

CAR-T requires harvesting a patient’s cells, engineering them individually over weeks, and infusing them after conditioning chemotherapy — at a cost per patient in the hundreds of thousands. That is defensible in refractory cancer and is not a delivery model for autoimmune diseases affecting millions.

Safety has also become pressing. Cases of a rare, severe hyperinflammatory syndrome have prompted trial pauses at large developers, and the risk calculation in autoimmune patients — frequently young, not facing imminent death — is far less forgiving than in cancer.

The three programmes

The lead, BLVD101, is a bispecific antibody blocking BAFF and APRIL, aimed at the kidney disease IgA nephropathy, with early data supporting quarterly dosing — more convenient than rivals dosed weekly or monthly.

BAFF and APRIL are survival factors for B cells and the plasma cells that produce antibodies. Blocking both removes support the autoreactive population depends on, which is a different route to depletion than killing the cells directly.

BLVD201 is a T-cell engager licensed from Metis TechBio for $20 million up front, designed for immune reset — the off-the-shelf approach to achieving what CAR-T does. BLVD301 targets a novel B-cell-driven autoimmune pathway.

Why the lead programme is the sensible one

Starting with IgA nephropathy rather than lupus is a considered choice.

IgA nephropathy is driven by deposition of a specific antibody in the kidney, causing progressive damage that leads a substantial proportion of patients to kidney failure. The disease has a clear measurable endpoint — protein in urine, and kidney function decline — which makes trials shorter and cleaner than lupus, where disease activity is assessed through composite indices that have defeated many programmes.

Quarterly dosing is also a genuine differentiator in a chronic condition where competitors require weekly or monthly administration.

The portfolio logic

Three programmes across different mechanisms is unusual for a company at this stage, and it reflects the uncertainty about which approach will reproduce the CAR-T result.

Depleting B cells via survival factor blockade, engaging T cells to kill them directly, and targeting a novel pathway are three distinct bets on how deep depletion must be and how it is best achieved. Whether antibody-based approaches can match what engineered cells do — persisting, proliferating, penetrating tissue — is the central open question in the field.

Why IgA nephropathy has become a crowded indication

Boulevard is entering a disease that has gone from neglected to intensely competitive within a few years, and the reasons are instructive about how drug development responds to regulatory signals.

IgA nephropathy was long managed with blood pressure control and general supportive care, with a substantial proportion of patients progressing to kidney failure over decades. Trials were unattractive because demonstrating an effect on kidney failure required following patients for many years.

That changed when regulators accepted reduction in urinary protein as a surrogate endpoint reasonably likely to predict long-term kidney benefit. Proteinuria can be measured in months rather than decades, which collapsed trial timelines and made the indication commercially viable overnight.

Several drugs have since been approved or advanced on that basis, working through different mechanisms — complement inhibition, endothelin and angiotensin blockade, targeted steroid delivery to the gut. A B-cell-directed approach addressing antibody production upstream is a further distinct angle, and quarterly dosing is a rational way to differentiate in a field where the therapeutic question is increasingly settled and the competition is on convenience.

Boulevard is betting that they can. Whether they will is what the next few years of data across many companies will determine. Business news, not investment advice.